$3.80 0.12 (+3.26%)
11/6/2009 4:00 PM

Santarus, Inc. (SNTS)

CAPS Rating: 3 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Current Price $3.80 Mkt Cap $220.57M
Open $3.62 P/E Ratio 0.00
Prev. Close $3.68 Div. (Yield) N/A (N/A)
Daily Range $3.51 - $3.92 Volume 299,308
52-Wk Range $1.05 - $3.89 Avg. Daily Vol. 208,000

SNTS News and Commentary

Related News and Articles

Caps

How do you think SNTS will perform vs the S&P 500?

Add Stock to Watchlist

All Members

55 Outperform
7 Underperform
 

All-Star Members

14 Outperform
2 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top SNTS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

docmase (< 20)
Submitted August 19, 2006

Santarus is a specialty pharmaceutical firm trying to promote a branded form of omeprazole (generic) in a market that is dominated by large pharmaceutical companies with significantly greater resources. The company has managed to grow revenues but… More

2 Comments | Reply | Report this Post
SNTS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about SNTS.

Recs

0
Member Avatar Brian7992 (< 20) Submitted: 8/11/2009 2:29:09 PM : Outperform Start Price: $3.12 SNTS Score: +14.08

Buy me now!

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar poppinkid (24.01) Submitted: 5/8/2008 9:12:28 PM : Outperform Start Price: $2.51 SNTS Score: +71.12

Highly underrated. GERD treatments are not that effective and LR PPI drugs don't provide immediate relief. Zegrid has a IR formulation that is significantly better than current prescriptions and OTC products. Hence, Schering and Glaxo's interest in co-promotion. This is a 14B market, and 5% of that market will make this an easy 4 bagger. The PAR case is causing hang over, but look for that to resolved and for profitability in 2009.

Report this Post 1 Comment | Reply | Permalink

Recs

0
Member Avatar RRUI (< 20) Submitted: 3/5/2008 2:58:35 PM : Outperform Start Price: $2.09 SNTS Score: +97.97

SNTS has been hampered primarily by a patent challenge by Par Pharm. and the stock took a huge hit when this claim came out primarily for two reasons. 1) CEO had stopped giving guidance on a call a few days before and 2) market thought that perhaps the patent challenge would further hamper the cash flow situation at SNTS. Realistically, this suit will probably be settled or won by SNTS. SNTS should reach profitability in Q4, however, the market is overlooking the two major deals SNTS has signed with Glaxo (for foreign distribution) and Schering for OTC distribution. Both companies are comfortable with the patents as should you be. I look for a volatile rocky ride from here...but up it should be. Cheers.

Report this Post 0 Comments | Reply | Permalink
View All 8 Pitches »

Leaderboard

Find the members with the highest scoring picks in SNTS.

Score Leader

TotoMMB

TotoMMB (99.67) Score: +110.67

The Score Leader is the member with the highest score across all their picks in SNTS.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
TotoMMB 99.67 2/20/2008 2/17/2009 Outperform 3Y $1.96 +93.87% -16.80% +110.67
wp1782 < 20 2/21/2008 Outperform 3W $1.99 +90.95% -18.19% +109.15
RRUI < 20 3/5/2008 Outperform 1Y $2.09 +81.82% -16.15% +97.97 1 Comment
robertvince 67.70 8/8/2007 Outperform 3Y $2.20 +72.74% -24.55% +97.29
xkrlongname 61.61 10/12/2007 Outperform 3Y $2.35 +62.05% -28.04% +90.08
PatientTrader 92.72 12/21/2007 Outperform 5Y $2.44 +55.74% -24.24% +79.98
mellonhead727 34.70 7/29/2008 Outperform NS $2.26 +68.14% -11.54% +79.68
tjdobb2stocks 48.48 12/26/2007 Outperform NS $2.46 +54.47% -24.89% +79.36
jloffswold 39.06 5/9/2008 Outperform 3Y $2.43 +56.38% -19.95% +76.33
pallidum 68.97 10/14/2008 Outperform 1Y $2.10 +80.95% +4.97% +75.98
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRothCapital 75.81 6/25/2009 Outperform NS $2.86 +32.87% +20.05% +12.82
TrackUBS 86.41 8/5/2008 Outperform NS $2.45 +55.10% -12.71% +67.81
TrackFBRCapitalM 75.98 6/29/2007 Outperform NS $5.37 -57.73% -16.96% -40.76 7/10/2008 @ $2.27
TrackRodmanRen < 20 6/29/2007 Outperform NS $5.37 -29.24% -25.26% -3.97
TrackMerriman < 20 5/24/2007 Outperform NS $6.83 -62.81% -5.91% -56.90 6/5/2008 @ $2.54
TrackWedbush < 20 10/19/2006 Outperform NS $8.85 -57.06% -16.60% -40.46
TrackSusquehanna 74.76 10/19/2006 Underperform NS $8.85 -38.08% +10.98% +49.06 7/2/2007 @ $5.48
TrackJimCramer < 20 10/19/2006 Underperform 3W $8.97 -57.64% -16.69% +40.94
TrackRBCCapMkts 81.74 8/9/2006 Outperform NS $5.30 -28.30% -11.07% -17.23
TrackJimCramer < 20 3/24/2006 Outperform 3W $6.25 +43.52% +4.91% +38.61 10/20/2006 @ $8.97

Featured Broker Partners